Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
about
Fingolimod for the treatment of neurological diseases-state of play and future perspectivesThe Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple SclerosisAlterations of the Ceramide Metabolism in the Peri-Infarct Cortex Are Independent of the Sphingomyelinase Pathway and Not Influenced by the Acid Sphingomyelinase Inhibitor FluoxetineSphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis.Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.Cardiovascular effects of fingolimod: A review article.Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: implications for multiple sclerosisChronic ethanol consumption profoundly alters regional brain ceramide and sphingomyelin content in rodentsExogenous S1P Exposure Potentiates Ischemic Stroke Damage That Is Reduced Possibly by Inhibiting S1P Receptor Signaling.Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke.Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab.A biological perspective of CSF lipids as surrogate markers for cognitive status in HIVFingolimod for the treatment of relapsing multiple sclerosis.Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosisRole of sphingomyelinases in neurological disorders.Altered Sphingolipid Balance in Capillary Cerebral Amyloid Angiopathy.Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhageCellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions.FTY720 attenuates excitotoxicity and neuroinflammation.Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelinationCardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents.Astrocyte-derived retinoic acid: a novel regulator of blood-brain barrier function in multiple sclerosis.Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination.Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency.C2-ceramide influences alveolar epithelial barrier function by downregulating Zo-1, occludin and claudin-4 expression.Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.Bioactive Lipids and Chronic Inflammation: Managing the Fire Within.[New therapeutic strategies for remyelination in multiple sclerosis].Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis.Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis.
P2860
Q27026175-324D7809-EDBA-43A0-9F0D-08905EA85B53Q28073377-817C4E90-AD8F-40D2-8EA7-41364778F6B5Q28270227-B32F0817-354E-4B97-9A36-625312F1B26BQ28546716-55A0B522-DDC6-4C9C-9A7C-2A9AED78FC81Q33755345-1FBCFBEE-263B-4093-9A68-1D10B4A7A734Q33759830-C7A5343C-24C0-4843-ACE2-9285A6C54FCCQ34518822-35D8BCBC-3201-4709-BB03-CAA96782F9D2Q34558943-0F2E8D2F-7D2A-4184-90AC-A324CD303ABAQ34720644-2719936F-AB4C-4D23-8864-751E3D62FCEDQ35212956-2DDE8376-9FF5-4673-9B74-28C1B0104BC8Q36241484-EE08634F-8F1F-467C-8281-797B33C254D0Q37209163-8330D6E0-FFBA-483D-940A-C151113AAF3DQ37389500-A150D3AC-942A-471B-986A-D984C25662C8Q37541514-3902081F-DE07-49DB-89E5-077FBBB433B5Q38112209-B5648CDD-18A3-4C12-8986-854EA334D06BQ38192006-9174A151-432A-44CC-94F9-A1F9ADBC775EQ38216015-A71B5248-3606-423C-8354-E0D83206AD79Q38560939-219E7F49-10DE-4682-B866-C51F3A295E08Q38818321-91F686AE-9796-4539-9D60-A5DABE31972DQ38873721-51E4518D-10E2-476A-A6DD-EC4B22B2DCA0Q39009182-CB613C2F-7430-48AE-8917-C0E6D0AC6289Q40613316-8301C1E8-B854-4ECD-A9E2-CFAC322EC43FQ42221029-A31E0A0B-3488-4C70-8990-AC2B56F537BBQ46025818-B75C7B5E-38C0-42F7-835C-C3DE75817638Q46426783-CDB9F097-0C84-407F-94E5-9ABC8A01B360Q46848816-797545F6-B0FB-4E5F-8B47-A2D1E6FDA56FQ47343678-30C24F11-D5BD-4F8F-AE34-4C1478A8762BQ47833651-9B246EF9-1B74-4451-8254-A01DF0AB8EE1Q48005842-A74724F6-E7E4-41C0-BC79-89067DBB4C28Q48649157-7848FC11-142E-4D09-BAC4-8A075CC0B5EBQ49679435-D21DF85C-6D33-4F97-9996-F21E96E4D66FQ53448928-14559CFF-967E-466D-92BA-D42A8E97AD80Q53669235-D2B96074-7692-4822-82FB-874548D3AB66Q55561652-89AF415F-E28A-4EB5-9B4D-59716F7D0E46
P2860
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Fingolimod attenuates ceramide ...... targeting reactive astrocytes.
@en
Fingolimod attenuates ceramide ...... targeting reactive astrocytes.
@nl
type
label
Fingolimod attenuates ceramide ...... targeting reactive astrocytes.
@en
Fingolimod attenuates ceramide ...... targeting reactive astrocytes.
@nl
prefLabel
Fingolimod attenuates ceramide ...... targeting reactive astrocytes.
@en
Fingolimod attenuates ceramide ...... targeting reactive astrocytes.
@nl
P2093
P2860
P921
P1476
Fingolimod attenuates ceramide ...... targeting reactive astrocytes.
@en
P2093
Arie Reijerkerk
Bert van het Hof
Christine Dijkstra
Gijs Kooij
Jack van Horssen
Maarten E Witte
Melissa A Lopes-Pinheiro
Nick Dekker
Paul van van der Valk
Philip G Nijland
P2860
P2888
P304
P356
10.1007/S00401-012-1014-4
P577
2012-07-19T00:00:00Z